OmniAbOABI +1.47%71 Shareholder Yield % is 0.78% as of Mar. 2026. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,295 Biotechnology companies, OmniAb ranks better than 76.6% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, OmniAb's Shareholder Yield % was 0.78%.
OmniAb (NAS:OABI) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
OmniAb Shareholder Yield % Related Terms
OmniAb Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for OmniAb's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OABI vs VNDA, AVIR, UPB: Shareholder Yield % Comparison
For the Biotechnology subindustry, OmniAb's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OmniAb Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OmniAb's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where OmniAb's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
OmniAb (OABI) has a Shareholder Yield % of 0.78% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on OmniAb and its competitors. According to the industry distribution chart, OmniAb ranks #303 out of 1295 companies in the Biotechnology industry, placing it in the top 23.4%.
Is OmniAb's Shareholder Yield % too high?
OmniAb's current Shareholder Yield % is 0.78%. Based on the distribution chart, OmniAb ranks #303 out of 1295 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Shareholder Yield % compare to VNDA and AVIR?
According to the Biotechnology industry distribution chart, OmniAb ranks #303 out of 1295 companies for Shareholder Yield %. This places OmniAb in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on OmniAb and its competitors. OmniAb's current Shareholder Yield % is 0.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current Shareholder Yield % is 0.78%. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For OmniAb (OABI), the current Shareholder Yield % is 0.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OmniAb (OABI) Overvalued in 2026?
Based on GuruFocus' analysis, OmniAb stock appears to be overvalued.
The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27.
GuruFocus considers OmniAb to be Fairly Valued.
Key valuation signals for OABI:
Shareholder Yield %: 0.78%
GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
71GF Score
Get the complete analysis for OABI
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OABI has been successfully added to your 
